2015
Catecholamine mechanisms in the prefrontal cortex: proven strategies for enhancing higher cognitive function
Berridge C, Arnsten A. Catecholamine mechanisms in the prefrontal cortex: proven strategies for enhancing higher cognitive function. Current Opinion In Behavioral Sciences 2015, 4: 33-40. DOI: 10.1016/j.cobeha.2015.01.002.Peer-Reviewed Original ResearchAttention deficit hyperactivity disorderPharmacological treatmentCognitive dysfunctionPrefrontal cognitive dysfunctionCognition-enhancing effectsMultiple psychiatric disordersSpecific intracellular pathwaysDeficit hyperactivity disorderPrefrontal catecholaminesClinical efficacyCatecholamine mechanismsADHD medicationNovel medicationsReceptor mechanismsPrefrontal cognitionPsychiatric disordersCatecholamine receptorsCatecholamine modulationHigher cognitive functionsCognitive functionPrefrontal cortexHyperactivity disorderImproved treatmentIntracellular pathwaysKey modulator
2012
Attention deficit hyperactivity disorder
Berridge C, Devilbiss D, Spencer R, Schmeichel B, Arnsten A. Attention deficit hyperactivity disorder. 2012, 303-320. DOI: 10.1017/cbo9780511980053.018.Peer-Reviewed Original ResearchAttention deficit hyperactivity disorderDeficit hyperactivity disorderHyperactivity disorderNeurodevelopmental disordersMore effective treatmentsMultiple sclerosisDisease groupEffective treatmentParkinson's diseaseBipolar disorderBrain disordersAlzheimer's diseaseClinical advancementTranslational neuroscienceSubstance abuseDiseaseDisordersField of psychiatryPublic healthCliniciansNeurologyPsychiatryPainSclerosisEpilepsyGuanfacine for the treatment of cognitive disorders: a century of discoveries at Yale.
Arnsten AF, Jin LE. Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale. The Yale Journal Of Biology And Medicine 2012, 85: 45-58. PMID: 22461743, PMCID: PMC3313539.Peer-Reviewed Original ResearchConceptsAttention deficit hyperactivity disorderPrefrontal cortexCognitive disordersHigher-order cognitive abilitiesDeficit hyperactivity disorderPFC cognitive functionCognitive abilitiesHyperactivity disorderCognitive functionMemory functionPFC functionAgonist guanfacineBrain regionsGuanfacineRecent researchNeurobiologyYale Medical SchoolCentury of discoveryDisordersTherapeutic targetTourette syndromePostsynaptic spinesEmotionsMemorySyndrome
2005
Chapter 11 Molecular Pharmacology and the Treatment of Tourette's Syndrome and Attention Deficit-Hyperactivity Disorder
Arnsten A. Chapter 11 Molecular Pharmacology and the Treatment of Tourette's Syndrome and Attention Deficit-Hyperactivity Disorder. 2005, 183-iv. DOI: 10.1016/b978-012738903-5/50012-6.Peer-Reviewed Original ResearchAttention deficit hyperactivity disorderDeficit hyperactivity disorderPrefrontal cortexTourette syndromeTherapeutic actionUse of guanfacineΑ2-adrenoceptor agonistNeuropsychiatric symptomsAppropriate medicationNeuromodulatory effectsTourette patientsPostsynaptic sitesNeurochemical environmentNeuropsychiatric illnessBrain circuitsSyndromePFC regulationBasic neuroscienceMolecular pharmacologyMolecular targetsDisordersGuanfacinePatientsPFC functionTreatment
1998
Catecholamine modulation of prefrontal cortical cognitive function
Arnsten A. Catecholamine modulation of prefrontal cortical cognitive function. Trends In Cognitive Sciences 1998, 2: 436-447. PMID: 21227275, DOI: 10.1016/s1364-6613(98)01240-6.Peer-Reviewed Original ResearchAttention deficit hyperactivity disorderPrefrontal cortexCognitive functionPrefrontal cortical cognitive functionUncontrollable stressCortical cognitive functionsWorking Memory FunctionDeficit hyperactivity disorderHyperactivity disorderPFC functionPFC dysfunctionNormal agingCognitive disordersCatecholamine modulationDopamine systemNeurochemical influencesMental disordersNeuropsychiatric disordersDisordersEnvironmental cuesCuesNeuromodulatory inputsMemoryFresh understandingHigh levels
1997
Noradrenergic Influences on Prefrontal Cortical Cognitive Function: Opposing Actions at Postjunctional α1 Versus α2-Adrenergic Receptors
Arnsten A, Steere JC, Jentsch DJ, Li BM. Noradrenergic Influences on Prefrontal Cortical Cognitive Function: Opposing Actions at Postjunctional α1 Versus α2-Adrenergic Receptors. Advances In Pharmacology 1997, 42: 764-767. PMID: 9328010, DOI: 10.1016/s1054-3589(08)60859-5.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPrefrontal cortexNE releaseΑ2 receptorsCognitive impairmentBeneficial effectsPFC functionBasal NE releasePrefrontal cortical cognitive functionΑ2-adrenergic receptorsCortical cognitive functionsPotential cognitive enhancersAttention deficit hyperactivity disorderMemory functionDeficit hyperactivity disorderPostsynaptic α1Α1d subtypesNE terminalsΑ-adrenoceptorsΑ2 agonistsLithium medicationNoradrenergic influenceOpen trialLithium pretreatmentΑ2A subtypeΑ2A receptors